Objectives: 301 patients have undergone prostate brachytherapy at the European Institute of Oncology, until July 2007. We present the outcome data of these patients. Methods: Data was analysed from a retrospective database of 301 consecutive patients, median age 70 years (range 39-85 years) treated with permanent prostate brachytherapy between October 1999 and July 2007. Patients were stratified into low (49.83%), intermediate (32.23%) and high (17.94%) risk as defined by the Memorial Sloan-Kettering Prognostic Index. Patients received 145 Gy brachytherapy (BT) as monotherapy (89.04%), 45 Gy external beam radiotherapy (EBRT) with 110 Gy BT (7.64%), or BT for failure after EBRT/ surgery (3.32%). Biochemical relapse-free survival (bRFS) and prostate-specific antigen (PSA) nadirs were analysed for treatment received in each risk group according to both definitions in use: ASTRO 1997 and 2006. Results: Median follow-up was 46 months (range 1-90 months). Prostate cancer-specific mortality at 7 years was 2.3% and 22.9% of the patients (7%) experienced biochemical failure according to the 1997ASTRO definition (3 consecutive PSA rising) and 15.9% according to the 2006 ASTRO definition (nadir + 2ng/ml). Taking into account the PSA bounce, only 10.9% of patients have had a failure (4% in the low risk group). The 5 years overall survival, 91%, was biased by the median age; 75% of the deaths were for other reasons. Conclusions: LDR prostate brachytherapy performs an excellent cause specific survival, a low toxicity and a good biochemical control in low risk tumors.
|Titolo:||Low-dose rate brachytherapy in the treatment of low-risk prostate cancer : the European Institute of Oncology Experience|
DE COBELLI, OTTAVIO (Penultimo)
ORECCHIA, ROBERTO (Ultimo)
|Parole Chiave:||prostate cancer ; low dose rate brachytherapy|
|Settore Scientifico Disciplinare:||Settore MED/24 - Urologia|
|Data di pubblicazione:||2008|
|Appare nelle tipologie:||01 - Articolo su periodico|